German researchers evaluating a possible new biomarker for pulmonary arterial hypertension (PAH) found that the molecule, known as chemokine CXC ligand 13 (CXCL13), was higher in the blood serum and lung tissue of people with PAH — suggesting a pathogenic role but one short of serving as a disease marker. The report,…
Search results for:
Social Clips
Living With Pulmonary Embolism
This is Emerson. He’s on his late 30s and was diagnosed with Pulmonary Embolism. Watch him talk about his personal experiences of suffering multiple PEs and about how it has impacted his daily life in terms of work, family, and dietary impact due to his medication. Learn more about Pulmonary…
News
Prognostic Factors for Pulmonary Hypertension Include Gender, Age, Chronic Diseases, Study Suggests
A new study published in the Journal of the American Heart Association reports that, in people with pulmonary hypertension (PH), females, middle-aged patients, and those with chronic diseases have an increased risk of mortality. Most current knowledge comes from small-scale or specialized studies. This is the first Taiwan nationwide…
Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is more prevalent in patients with pulmonary embolisms than was previously thought. Although the rate may be at least twice as high as previously identified, many patients do not undergo the…
Soluble ST2 (sST2) protein could be an additional non-invasive biomarker for monitoring patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing interventional treatment with balloon pulmonary angioplasty (BPA), a study suggests. The study, “Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated…
The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with…
According to the Cleveland Clinic, pulmonary hypertension (PH) is rare pulmonary disease. In PH patients, arteries become more narrow, making it difficult for blood to flow through the vessels between the heart and the lungs, increasing the blood pressure in the pulmonary arteries. MORE: The difficulties of diagnosing pulmonary arterial hypertension What causes…
This podcast series, created and produced by phaware, is being offered as a regular guest feature on Pulmonary Hypertension News to bring the voices and life experiences of PH patients, family members, caregivers, healthcare specialists, and others to our readers. You may listen to the podcast directly, or…
Pulmonary hypertension (PH) life expectancy can vary widely depending on disease type, how severe PH is, and how quickly it is diagnosed and treated. While PH can be a serious and progressive disease, advances in diagnosis, treatment, and ongoing monitoring have improved the outlook for many people living with…
Social Clips
Riociguat Clinical Trials for Pulmonary Hypertension
In this webcast shared by the American College of Cardiology, we find out more about the use of riociguat for the treatment of pulmonary hypertension (PH). Â Two-year study of riociguat as CTEPH treatment identifies predictive disease markers. Find…